NANOBIOTIX Announces Two Key Supervisory Board Additions Intended to Further Equip the Company for Sustainable Long-Term Growth

Core Insights - NANOBIOTIX has announced the nominations of Dr. Margaret A. Liu and Ms. Anat Naschitz as observers to its Supervisory Board, aiming to enhance its strategic initiatives in oncology and expand development opportunities [1][2][4]. Company Overview - NANOBIOTIX is a late-stage clinical biotechnology company focused on pioneering nanoparticle-based therapeutic approaches for cancer and other major diseases [1][6]. - The company is headquartered in Paris, France, and is listed on Euronext Paris and the Nasdaq Global Select Market [7]. Key Personnel - Dr. Margaret A. Liu is a global expert in vaccines, gene therapy, and cancer immunotherapy, currently serving as CEO of PAX Therapeutics and holding various board positions [2][3]. - Ms. Anat Naschitz is a life science investor and entrepreneur with over three decades of experience in biotech and pharmaceuticals, currently co-founder and CEO of 9xchange [3][4]. Strategic Goals - The company aims to leverage the expertise of Dr. Liu and Ms. Naschitz to drive the development of nanophysics-based therapies and enhance collaboration opportunities beyond its current focus on NBTXR3 [2][4]. Future Actions - The nominations of Dr. Liu and Ms. Naschitz will be submitted for ratification at the next shareholders' meeting [5].